Weight management research
5Studied in adults with obesity without diabetes.
What does it do?
An investigational triple agonist with phase-3 evidence for obesity and diabetes; not FDA-approved.
Approved & studied uses
Type 2 diabetes research
4Early human development includes glucose-control studies.
Community uses Reported, unvalidated
Weight
31Weight reduction, appetite and maintenance research.
Diabetes
31Glycemic control and insulin sensitivity.
Other outcomes
31Lipids, BP, liver fat and obesity-related complications; outcome-specific evidence varies.
Reasons people report using it; these do not establish benefit.31
Evidence limits
View research →Long-term clinical outcomes and risks are still being studied.1
6 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.
Evidence definitions →Key safety information
All risks →Gastrointestinal effects
Gastrointestinal events were the most common adverse events in TRIUMPH-1.5
Not FDA approved; investigational as of October 2026.
Amino-acid sequence
- Tyr
- Aib
- Gln
- Gly
- Thr
- Phe
- Thr
- Ser
- Asp
- Tyr
- Ser
- Ile
- αMeLeu
- Leu
- Asp
- Lys
- Lys*
- Ala
- Gln
- Aib
- Ala
- Phe
- Ile
- Glu
- Tyr
- Leu
- Leu
- Glu
- Gly
- Gly
- Pro
- Ser
- Ser
- Gly
- Ala
- Pro
- Pro
- Pro
- Ser
39 residues · N → C29
Length39-residue backbone
Molecular weight · Da4731.3 Da (peptide moiety)
Formula, sequence notation & identity
Y–Aib–Q–G–T–F–T–S–D–Y–S–I–αMeL–L–D–K–K*–A–Q–Aib–A–F–I–E–Y–L–L–E–G–G–P–S–S–G–A–P–P–P–SAib at 2 and 20; αMeL = alpha-methylleucine at 13; K* at 17 carries the lipidated side chain. C-terminal amide. Backbone positions include the modifications described in the systematic identity.
Lipidated GIP/GLP-1/glucagon receptor agonist.
Formula excludes counterions. The catalog lists a sodium salt with variable sodium content; this is not a retail-vial identity test.
Pep-Pedia identity details
39 amino acids · 4,731.33 Da
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-SerReference description; checked chemical identity above takes precedence when available.31
Pharmacokinetics
How long does it stay in the body?
Human data
Reported half-lifeApproximately 6 days4
Route / formulationSubcutaneous
50%of reference level
Illustrative model using reported human data.
About 3% remaining after 30 d
Five half-lives in this simplified model. This is not a prediction of when effects stop.
Evidence and model details
Reported human estimate; albumin binding prolongs exposure. An idealized elimination curve does not model absorption, accumulation or individual response.
Population: Adults with type 2 diabetes in a phase 1b trial
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
Unverified reference estimateNot independently confirmed
Reference half-life6 days30
Route / formulationSource page: Injectable. Exact PK route not verified.
This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement.
50%of reference level
Illustrative scenario using an unverified reference estimate.
About 3% remaining after 30 d
Five half-lives in this estimated model. This is not a prediction of when effects stop.
Evidence and model details
Population: Not established by the reference estimate
Source’s stated attribution: Phase 2 Clinical Trial Data (Eli Lilly)
Source’s reported peak time: 1 day. This has not been independently confirmed and is not used in the elimination curve.
100 × 2−time / half-life. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.
What to expect
Study outcomes
Weight changed over 80 weeks
TRIUMPH-1 reported mean changes of −17.6%, −23.7% and −25.0% for 4, 9 and 12 mg versus −3.9% for placebo (treatment-regimen estimand).5
Reported timelines
Reference & communitySource expectations
Appetite 1–4 weeks, continuing change over months; its staged percentage-loss predictions are not personal forecasts.31
Phase 3
Trial outcomes at 80 weeks; interpretation depends on estimand/population.31
These are reported timelines, not a prediction of your response.
Community poll Results availability
Results were not available when checked. This does not mean there were no responses.
Protocols
Doses & schedules
Compare purpose, amount, route, frequency, and duration.
Source corrections
No established one-hour contraceptive rule or safe research-product combination.
Scroll to compare all columns →
| Route | Dose | Frequency | Goal / evidence | Duration | References |
|---|---|---|---|---|---|
| SubQSubcutaneous | 4 mgMaintenance | Once weekly | Weight reduction (TRIUMPH-1)Human study | 80 weeks | 5 |
Population 2,339 adults with obesity without diabetes Context Randomized maintenance targets after trial escalation, not starting-dose instructions. Source dose wording 4, 9 or 12 mg maintenance | |||||
| SubQSubcutaneous | 9 mgMaintenance | Once weekly | Weight reduction (TRIUMPH-1)Human study | 80 weeks | 5 |
Population 2,339 adults with obesity without diabetes Context Randomized maintenance targets after trial escalation, not starting-dose instructions. Source dose wording 4, 9 or 12 mg maintenance | |||||
| SubQSubcutaneous | 12 mgMaintenance | Once weekly | Weight reduction (TRIUMPH-1)Human study | 80 weeks | 5 |
Population 2,339 adults with obesity without diabetes Context Randomized maintenance targets after trial escalation, not starting-dose instructions. Source dose wording 4, 9 or 12 mg maintenance | |||||
| SubQ | 2 mgStarting dose | Weekly x 4 weeks, then increase | Phase 3 start (TRIUMPH)Reference report | Continuous therapy - effects reverse upon discontinuation | 31 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. No established one-hour contraceptive rule or safe research-product combination. Source tabs Injectable | |||||
| SubQ | 4, 9, or 12 mg | Once weekly | Phase 3 targets (TRIUMPH)Reference report | Continuous therapy - effects reverse upon discontinuation | 31 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. No established one-hour contraceptive rule or safe research-product combination. Source tabs Injectable | |||||
| SubQ | 0.5-1 mgStarting dose | Once weekly | Community start (not in trials)Reference report | Continuous therapy - effects reverse upon discontinuation | 31 |
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. No established one-hour contraceptive rule or safe research-product combination. Source tabs Injectable | |||||
No protocols match these filters.
Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.
Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.
Injectable
- Use period
- Continuous therapy - effects reverse upon discontinuation
- Break
- No cycling required - designed for continuous use
Reported timing
Any time of day, maintain same day each week for consistency
Side effects & safety
Gastrointestinal effects
Gastrointestinal events were the most common adverse events in TRIUMPH-1.
5Heart rate
Dose-related heart-rate increases occurred in phase 2.
1Product uncertainty
FDA identifies retatrutide as unapproved; trial findings do not validate online research products.
3Common
GI symptoms, altered skin sensations and heart-rate increases.
Urgent
Severe abdominal/RUQ pain, repeated vomiting/diarrhea, dehydration, hypoglycemia or excessive weight loss.
Context
MTC/MEN2 risk and pregnancy require assessment; community starts differ from trial titration.
Not a complete safety screen. Discuss health decisions with a qualified clinician.
Combinations & interactions
11 entriesCheck cautions and reported pairings. A compatibility claim does not establish that a combination is safe.
Tirzepatide
Avoidance reportedIncretin overlap.31
Reference report · Pep-Pedia label: Avoid CombinationSemaglutide
Avoidance reportedGLP-1 overlap.31
Reference report · Pep-Pedia label: Avoid CombinationCagrilintide
Caution reportedGI burden; combination unestablished.31
Reference report · Pep-Pedia label: Use CautionInsulin
Caution reportedHypoglycemia risk.31
Reference report · Pep-Pedia label: Monitor CombinationOral contraceptives
Caution reportedSource timing rule unverified.31
Reference report · Pep-Pedia label: Requires TimingWarfarin
Caution reportedINR may change.31
Reference report · Pep-Pedia label: Monitor CombinationMetformin
Unverified pairingBackground trial therapy.31
Reference report · Pep-Pedia label: CompatibleSGLT2 inhibitors
Unverified pairingBackground trial therapy.31
Reference report · Pep-Pedia label: CompatibleBPC-157
Unverified pairingUntested; no proven GI protection.31
Reference report · Pep-Pedia label: CompatibleNAD+
Unverified pairingUntested pairing.31
Reference report · Pep-Pedia label: CompatibleOther incretin or glucose-lowering drugs
Not establishedThe cited obesity trial does not establish safety of self-directed combinations with semaglutide, tirzepatide or insulin.5
Research contextNo matching interactions. Try another name or filter.
Reconstitution calculator
Enter your peptide amount and container size. Get a volume and a simple measurement scale.
Suggested final volume mL
Estimated water to add≈ mL
For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.
1 pen unit (one dial step)=
Amounts below are total blend mass. Ingredient amounts are listed separately.
| Pen units | Amount | Volume |
|---|
Ingredients per unit
Other simple scales
Convert a specific amount
Enter an amount to calculate its volume and device setting.
Calculation & assumptions
The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.
The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.
V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗Reconstitution
No FDA-approved retatrutide formulation or universal reconstitution instruction exists.3
Research powders
A concentration calculation cannot establish a product's identity, sterility, stability or suitability for injection.3
Reference preparation details
Reported handling information, not a validated formulation or instruction to prepare an injectable product.
Injectable
Pep-Pedia describes a research-powder preparation using bacteriostatic water.
- Solvents mentioned
- Bacteriostatic water
- Reported parameters
- Prepared solution: 2–8°C; reported interval 28 days. · The source explicitly cautions against bacteriostatic saline because of precipitation or cloudiness.
The source describes gentle mixing and avoiding vigorous shaking.
The saline warning and 28-day interval are secondary-source claims, not a validated stability specification for every research vial.
Appearance & documentation
Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.
Reported appearancePharmaceutical-grade white powderReported appearanceProper cold chain maintenanceReported appearanceClear reconstituted solutionReported appearanceStable extended half-life effectsReported variationSource verification criticalReported concernRapid tolerance or effectiveness lossReported concernUnusual side effect profile
31Vial sizes
Each amount below appears in at least two of four catalogs checked on October 12, 2026. This is a sample of recurring listings, not a ranking of the most popular sizes.
Labels describe nominal contents, not a dose or supplier endorsement. Approved and research products are not interchangeable.
Storage after mixing
Reconstituted research vials
Refrigerated lifetime not established
The checked sources do not establish how long this research preparation remains stable and sterile after mixing.31
Full storage notes from Pep-Pedia
31Lyophilized powder at room temperature; reconstituted solution refrigerated
Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.
Pen & syringe measurements Scales, capacity & references
Pen & syringe measurements
Device units measure volume. Concentration determines the amount in mg.
1 notch = 0.01 mL
Documented 1-unit V2 models
- One dial increment
- 1 unit
- Cartridge capacity
- 3 mL
- Maximum setting
- 60 units · 0.60 mL
Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.
1 unit = 0.01 mL
100 units = 1 mL
- 10 units
- 0.10 mL
- 30-unit capacity
- 0.30 mL
- 50 / 100-unit capacity
- 0.50 / 1 mL
Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.
Use the mL scale
mL syringes and calibrated pipettes
- 0.01 mL
- 10 µL
- 0.10 mL
- 100 µL
- Amount
- mL × mg/mL
Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.
3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.
Device references
AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.Research findings
Human trialsSource context
No established one-hour contraceptive rule or safe research-product combination.
Compound identity & other names
An investigational GLP-1, GIP and glucagon receptor agonist studied for obesity and metabolic disease. Human trials show substantial weight loss, but trial material and online research vials are not interchangeable.
Other names: Reta · LY3437943 · GLP-3
Not FDA approved; investigational as of October 2026.
How it may work
Activates GIP, GLP-1 and glucagon receptors affecting appetite, glucose regulation and energy expenditure.31
Phase 2: 24.2% mean weight loss
In 338 adults with obesity or overweight without diabetes, the 12 mg group lost a mean 24.2% at 48 weeks versus 2.1% with placebo. This was a controlled trial, not a prediction of an individual's response.
1Phase 3: 25.0% mean loss in published analysis
The September 29, 2026 TRIUMPH-1 paper reports 25.0% mean weight reduction with 12 mg versus 3.9% with placebo at 80 weeks (treatment-regimen estimand). The earlier 28.3% sponsor headline used a different efficacy analysis; these estimates should not be interchanged.
52Source checks & newer research
Retatrutide for treatment of obesity: TRIUMPH-1
Phase 3 randomized 80-week trial published September 29, 2026; dose groups were 4, 9 and 12 mg weekly versus placebo. Trial estimates must be identified by estimand rather than presented as guaranteed weight loss.
Phase 3 randomized trial32Lilly: TRIUMPH-1 topline results
Sponsor reported 28.3% mean weight reduction at 80 weeks for 12 mg using its efficacy estimand; not approval or a forecast for individuals.
Sponsor phase 3 report33Research areas and evidence gaps
Weight management research. Studied in adults with obesity without diabetes.5
Type 2 diabetes research. Early human development includes glucose-control studies.4
- Long-term clinical outcomes and risks are still being studied.
- Published trial findings do not establish the identity, sterility or potency of retail research material.
Community reports Unvalidated
Pep-Pedia describes interest in appetite and weight changes, and explicitly distinguishes community starting amounts from the TRIUMPH trial schedule.8
A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.
Search coverage and review status
The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.
- Checked
- 2026-10-12
- Search
- retatrutide 2026 phase 3 site:pubmed.ncbi.nlm.nih.gov
- Catalog
- Pep-Pedia ↗ · 16 listed references retained
- Targeted search, not an exhaustive systematic review.
- Bibliography-only entries are retained for traceability and are not treated as verified findings.
AI-prepared summaries. Independent medical editorial review is pending.
References
Original sources and review status. Open a reference to read its summary.
1Triple-Hormone-Receptor Agonist Retatrutide for Obesity — phase 2Primary source checked
AI-PREPARED SUMMARY
Randomized obesity trial: the 12 mg group averaged 24.2% weight loss at 48 weeks; placebo averaged 2.1%. GI effects were common.
Phase 2: 24.2% mean weight loss
In 338 adults with obesity or overweight without diabetes, the 12 mg group lost a mean 24.2% at 48 weeks versus 2.1% with placebo. This was a controlled trial, not a prediction of an individual's response.
Pep-Pedia bibliography · Checked 2026-10-12
2Lilly: TRIUMPH-1 phase 3 topline resultsPrimary source checked
AI-PREPARED SUMMARY
Sponsor announcement reports 28.3% mean weight reduction at 80 weeks with 12 mg. It is a topline report, not an independent review.
Phase 3: 25.0% mean loss in published analysis
The September 29, 2026 TRIUMPH-1 paper reports 25.0% mean weight reduction with 12 mg versus 3.9% with placebo at 80 weeks (treatment-regimen estimand). The earlier 28.3% sponsor headline used a different efficacy analysis; these estimates should not be interchanged.
Pep-Pedia bibliography · Checked 2026-10-12
3FDA concerns with unapproved GLP-1 drugsReview status not recorded
AI-PREPARED SUMMARY
FDA identifies retatrutide as unapproved and raises concerns about products marketed directly to consumers.
4Retatrutide phase 1b: human pharmacokinetics and metabolic effectsReview status not recorded
AI-PREPARED SUMMARY
Weekly subcutaneous retatrutide was studied in adults with type 2 diabetes; the reported half-life was approximately six days.
5TRIUMPH-1: retatrutide for obesity (peer-reviewed phase 3)Review status not recorded
AI-PREPARED SUMMARY
Published September 29, 2026. The treatment-regimen estimate differs from the earlier sponsor efficacy headline.
Phase 3: 25.0% mean loss in published analysis
The September 29, 2026 TRIUMPH-1 paper reports 25.0% mean weight reduction with 12 mg versus 3.9% with placebo at 80 weeks (treatment-regimen estimand). The earlier 28.3% sponsor headline used a different efficacy analysis; these estimates should not be interchanged.
6Retatrutide identity and human analytical detection studyReview status not recorded
AI-PREPARED SUMMARY
Original analytical work describes the 39-residue backbone and lipidated side chain. Its small observational exposure series is not an efficacy trial.
7LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialPrimary source checked
AI-PREPARED SUMMARY
Weekly subcutaneous retatrutide was studied in adults with type 2 diabetes; the reported half-life was approximately six days.
Pep-Pedia bibliography · Checked 2026-10-12
8Pep-Pedia: retatrutide — community referenceCommunity source checked
AI-PREPARED SUMMARY
Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.
9Research catalog: labeled vial examplesCatalog checked
AI-PREPARED SUMMARY
Catalog lists a 10 mg lyophilized research vial. These are seller label examples, not verified contents, market-frequency estimates or supplier endorsements.
10Cayman Chemical: retatrutide sodium salt chemical identityCatalog checked
AI-PREPARED SUMMARY
Chemical reference for the peptide formula and 4731.3 formula weight; the sodium counterion quantity is variable. Not a clinical preparation guide.
11Phase III TRIUMPH-2 and TRIUMPH-3 - Eli Lilly (July 2026)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The secondary page reports TRIUMPH-2/3 topline weight and glycemic outcomes. Its cardiovascular interval crosses no effect, and the cited release needs confirmation.
Reported population / model
Human
Reported study details
4-12mg weekly · 80 weeks · TRIUMPH-2 20.8% weight / 1.6% A1C; TRIUMPH-3 22.6% weight
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
12ADA 2026 Scientific Sessions - OSA and OA Basket Data (June 2026)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports sleep-apnea and knee-pain substudy changes from a conference presentation; it does not provide a verified primary analysis here.
Reported population / model
Human
Reported study details
TRIUMPH-1 substudies · OSA AHI reduced 60.6%; WOMAC pain reduced 73.1%
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
13Phase III TRANSCEND-T2D-1 Trial - Eli Lilly (March 2026)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports up to 16.8% weight loss and roughly two HbA1c points in early diabetes, with gastrointestinal events and treatment discontinuations.
Reported population / model
Human
Reported study details
4-12mg weekly · 40 weeks · 16.8% weight loss, 2.0% A1C reduction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
14Phase III TRIUMPH-4 Trial - Eli Lilly (Dec 2025)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The source reports 28.7% weight loss at 12 mg alongside knee-pain improvement, with substantial discontinuation and dysesthesia rates.
Reported population / model
Human
Reported study details
9-12mg weekly · 68 weeks · 28.7% weight loss (71.2 lbs)
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
15MASLD Substudy - Nature Medicine (2024)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: A liver-fat substudy reportedly reduced liver fat by about 82%, with frequent normalization at higher doses; this surrogate is distinct from clinical liver outcomes.
Reported population / model
Human
Reported study details
8-12mg weekly · 24 weeks · 82% liver fat reduction
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
16TRIUMPH-Outcomes Cardiovascular Study (2024-2029)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: This is a planned cardiovascular/kidney outcome trial; the card gives no completed outcome result and its stated regimen requires registry confirmation.
Reported population / model
Human
Reported study details
8mg weekly · 248 weeks · 10,000 participants with ASCVD
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
17Phase II Type 2 Diabetes Study - Lancet (2023)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: The phase 2 diabetes study reportedly improved both weight and HbA1c; the card uses different glycemic maxima, so dose/estimand details matter.
Reported population / model
Human
Reported study details
0.5-12mg weekly · 36 weeks · 16.9% weight loss, -2.02% HbA1c
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
18Phase I Pharmacokinetics - Cell Metabolism (2022)Pep-Pedia report · Primary source not checked
AI-PREPARED SUMMARY
Pep-Pedia reports: Early human work characterized dose-related exposure and an approximately six-day half-life; a small early trial cannot establish comprehensive safety.
Reported population / model
Human
Reported study details
Single ascending dose · 12 weeks · Established 6-day half-life
Reported by Pep-Pedia; the linked publication, design, doses and result have not been independently verified here.
Read the Pep-Pedia report ↗Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12
19Lilly reports first-quarter 2026 financial results, raises full year guidance and highlights momentum of new medicinesLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
20Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trialsLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
21Structural insights into triple agonism at GLP-1R, GIPR and GCGR by retatrutideLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
22LY3437943 triple receptor agonist demonstrates superior efficacy compared to incretin therapiesLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
23Pharmacokinetics and pharmacodynamics of retatrutide (LY3437943), a novel triple glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonistLinked reference · Not independently reviewed
REFERENCE NOTE
Listed in Pep-Pedia’s bibliography; the linked publication and its findings have not been independently verified in this pass.
Pep-Pedia bibliography · Checked 2026-10-12
24Prime Lab Peptides: 24 mg vial listingCatalog checked
AI-PREPARED SUMMARY
Lists a single vial labeled 24 mg of lyophilized retatrutide. Checked October 12, 2026. Used only to document the labeled amount; contents, supplier quality and suitability for human use were not independently verified.
25Peptides Costa Rica: vial-size specification tableCatalog checked
AI-PREPARED SUMMARY
Lists 5, 10, 12, 15, 20, 24, 25, 30, 40, 50 and 60 mg vial labels. Checked October 12, 2026. Used only as packaging evidence, not to validate the seller’s preparation, storage or medical claims.
26BulkGLP: research vial labelsCatalog checked
AI-PREPARED SUMMARY
Lists 10, 12, 15, 20, 30 and 50 mg vial options. Checked October 12, 2026. Nominal label amounts and the seller’s reported analytical results are distinct; neither the contents nor testing were independently verified here.
27NH Peptides: research vial labelsCatalog checked
AI-PREPARED SUMMARY
Lists 10, 20, 30, 40 and 60 mg research vial options. Checked October 12, 2026. This establishes listed packaging amounts only, not market prevalence, product quality or fitness for injection.
28FDA: errors converting milligrams, milliliters and syringe unitsPrimary source checked
AI-PREPARED SUMMARY
FDA describes U-100 syringe conversion, including 5 units = 0.05 mL, and reports errors caused by confusing units, volume and concentration. The alert concerns compounded semaglutide; it supports the measurement explanation, not retatrutide preparation or dosing. Checked October 12, 2026.
29NIH NCATS GSRS: retatrutide sequence and systematic identityPrimary source checked
AI-PREPARED SUMMARY
Sequence and modifications checked October 12, 2026. Aib at 2 and 20; αMeL = alpha-methylleucine at 13; K* at 17 carries the lipidated side chain. C-terminal amide. Backbone positions include the modifications described in the systematic identity.
30Pep-Pedia: Retatrutide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity source checked
AI-PREPARED SUMMARY
Lists a half-life of 6 days and a peak time of 1 day. Stated attribution: Phase 2 Clinical Trial Data (Eli Lilly). This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.
Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12
31Pep-Pedia: Retatrutide — route-specific referenceReference page checked; underlying claims require separate verification.Community source checked
AI-PREPARED SUMMARY
Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.
Content coverage audit · Checked 2026-10-12
32Retatrutide for treatment of obesity: TRIUMPH-1Primary source checked
AI-PREPARED SUMMARY
Phase 3 randomized 80-week trial published September 29, 2026; dose groups were 4, 9 and 12 mg weekly versus placebo. Trial estimates must be identified by estimand rather than presented as guaranteed weight loss.
Retatrutide for treatment of obesity: TRIUMPH-1
Phase 3 randomized 80-week trial published September 29, 2026; dose groups were 4, 9 and 12 mg weekly versus placebo. Trial estimates must be identified by estimand rather than presented as guaranteed weight loss.
Additional primary-source check · Checked 2026-10-12
33Lilly: TRIUMPH-1 topline resultsPrimary source checked
AI-PREPARED SUMMARY
Sponsor reported 28.3% mean weight reduction at 80 weeks for 12 mg using its efficacy estimand; not approval or a forecast for individuals.
Lilly: TRIUMPH-1 topline results
Sponsor reported 28.3% mean weight reduction at 80 weeks for 12 mg using its efficacy estimand; not approval or a forecast for individuals.
Additional primary-source check · Checked 2026-10-12